A cut-off of 0.38 kPa/yearfor the pathologic increase in liver stiffness may allow detection of developing cystic fibrosis (CF)-associated liver disease (CFLD) when used with follow-up transient elastography (TE) measurements, a new longitudinal study reveals.
Exposure to statins may lower the risk of hepatic decompensation and mortality, as well as reduce portal hypertension, in patients with chronic liver diseases (CLDs), according to a systematic review and meta-analysis.
Adjuvant adoptive immunotherapy (AIT) for hepatocellular carcinoma (HCC) patients who have received therapy is both safe and effective for improving mortality rates and tumour recurrence, a new meta-analysis shows.
Prognosis in end-stage liver disease has highly significant association with plasma levels of sphingosine-1-phosphate (S1P), such that patients with low circulating S1P levels have lower 3-month and 1-year survival compared with those who have high S1P levels, a new study shows.
Simultaneous liver and kidney transplantations (SLK) in polycystic diseases carried out through a one-step midline approach is effective, feasible, safe and may help avoid pre-transplant renal replacement therapy, a new study shows.
Treatment with low-dose on-demand hepatitis B immunoglobulin added to entecavir led to decreased hepatitis B virus (HBV) recurrence rate without development of resistance following liver transplantation, according to an assessment of a pilot study.
Sanofi’s approach in providing medical education has evolved over the years, by not only limiting the content to disease management and patient outcomes, but also taking into consideration of the various challenges faced by doctors across the different sectors.
Excerpted from a speech by Datuk Seri Dr. S. Subramaniam, Minister of Health, at the launch of the new palliative care symbol and palliative care photography exhibition by Hospis Malaysia, Kuala Lumpur, 25 April